Results 171 to 180 of about 57,293 (304)
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz +8 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Divergent acetyl-CoA binding modes mediate allosteric inhibition of bacterial hybrid-type malic enzymes. [PDF]
Sassa M +4 more
europepmc +1 more source
Abstract Background and Purpose Extensive evidence indicates that lipid accumulation causes renal tubular injury, which further contributes to diabetic nephropathy (DN) progression. Short‐chain fatty acids (SCFAs) play an important role in the maintenance of cellular metabolic health.
Jiayin Tao +12 more
wiley +1 more source
Critical role of the mast cell/tryptase/PAR2 axis in anastrozole‐induced pain
Abstract Background and Purpose Anastrozole, an aromatase inhibitor, is used to treat postmenopausal women with hormone receptor‐positive breast cancer, but also induces musculoskeletal pain and can lead to therapeutic regimen suspension. Aromatase inhibitors promote the release of pro‐inflammatory substances from sensitised nerve fibres, which might ...
Maria Fernanda Pessano Fialho +5 more
wiley +1 more source
Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen +2 more
wiley +1 more source
How ATP and dATP reposition class III ribonucleotide reductase cone domains to regulate enzyme activity. [PDF]
Andree GA +6 more
europepmc +1 more source
Multiple allosteric sites are involved in the modulation of insulin‐degrading‐enzyme activity by somatostatin [PDF]
Grazia Raffaella Tundo +7 more
openalex +1 more source

